Bank of Nova Scotia
VIR icon

Bank of Nova Scotia’s Vir Biotechnology VIR Stock Holding History

Bank of Nova Scotia’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$253K – 1226
2022
Q4 		$253K Sell
10,000
-22,683
-69% -$556K ﹤0.01% 1070
2022
Q3 		$630K Buy
32,683
+3,133
+11% +$79.6K ﹤0.01% 924
2022
Q2 		$753K Buy
29,550
+5,189
+21% +$121K ﹤0.01% 911
2022
Q1 		$627K Sell
24,361
-9,940
-29% -$295K ﹤0.01% 1009
2021
Q4 		$1.51M Buy
34,301
+24,808
+261% +$972K ﹤0.01% 933
2021
Q3 		$413K Sell
9,493
-1,177
-11% -$51K ﹤0.01% 1051
2021
Q2 		$504K Buy
10,670
+3,442
+48% +$156K ﹤0.01% 979
2021
Q1 		$371K Sell
7,228
-12,712
-64% -$685K ﹤0.01% 993
2020
Q4 		$534K Buy
+19,940
New +$648K ﹤0.01% 895

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Bank of Nova Scotia's VIR Position: Q1 2023 in Review

Bank of Nova Scotia sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 10,000 shares — an estimated $253K sold.

Bank of Nova Scotia first reported a position in VIR in Q4 2020 and held it in 9 quarters. The position peaked at $1.51M in Q4 2021. 231 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Bank of Nova Scotia reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Bank of Nova Scotia sold 10,000 Vir Biotechnology shares in Q1 2023, an estimated $253K.
  • Bank of Nova Scotia first reported a position in Vir Biotechnology in Q4 2020 and held it in 9 quarters.
  • Bank of Nova Scotia's Vir Biotechnology position peaked at $1.51M in Q4 2021.
  • 231 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Bank of Nova Scotia's 13F filing for Q1 2023, filed 11 May 2023.